Loading, please wait ...


News Analytics

.
Polyphor today announced the enrollment of the first patient in its FORTRESS clinical trial, the pivotal Phase III study evaluating balixafortide (POL6326) in combination with eribulin for the treatment of patients with HER2 negative, locally recurrent or metastatic breast cancer (MBC).

Subject Matter

  • Healthcare 54.05%
    • Hospitals, doctors and medical care 100.00%
  • Science and technology 45.95%

Emotional Reaction

Sentiment

Positive

Neutral

Negative

Definitions